Ingredients For A Successful Cell Death: A Sip Of Resveratrol And A Full P53
A number of studies show that resveratrol induces cell death in different types of cancers, both in humans and animal models. However, the potential anti-tumor effect of resveratrol is still little understood as the compound seems to induce cell death in a number of cancer cells whereas in others no effect is observed, even when massive doses of resveratrol are used. A phase I study on the pharmacokinetic properties of resveratrol as a potential cancer chemopreventive agent has concluded that consumption of high levels of resveratrol would be insufficient to provide the amounts of resveratrol needed to elicit its chemopreventive proprieties. Nevertheless, a few ongoing clinical trials investigate the effects of resveratrol on a number of diseases, including colon cancer.
More recently, the anti-tumor functions of resveratrol have been associated to p53, a protein responsible for suppressing tumor development in the body. p53 is one of the main blockers of the cell cycle, leading cells to the death row. A faulty p53 is unable to suppress cell growth, which ultimately results in tumor development. Indeed, studies have shown that p53 is either defective or simply absent in most cancers.
To investigate whether resveratrol anti-tumor effects, as observed in some cancer cell lines, depend on the status of the cell's p53 gene, a group led by Dr Jerson L. Silva at the Universidade Federal do Rio de Janeiro, Brazil, tested the effects of resveratrol in H1299, a human non-small lung carcinoma cell line carrying only a partial fragment of the p53 gene and compared the results with MCF-7, A549, and H460, which are cancer cell lines carrying normal copies of p53. The study shows that although resveratrol affects the viability of all cancer cell lines, MCF-7, A549, and H460 are more sensitive to the effects of resveratrol than H1299. While MCF-7 cell lines die after exposure to resveratrol, H1299 remains resistant. Additional findings indicate that the toxic effect of resveratrol on MCF-7, A549, and H460 cell lines is mediated by p53.
The research group then went one step further and asked what would happen if a normal copy of p53 is added to the previously p53-defective H1299 cancer cell line. The results, published this week in PLOS ONE, show that introduction of a normal copy of p53 in H1299 turns the cell line sensitive to the anti-tumor effects of resveratrol, similarly to that observed in other cancer cell lines (MCF-7, A549, and H460). "Our findings may have potential applications in cancer cell lines that are under p53 control," says Dr Danielly Ferraz da Costa, the first author of the study. "Also, the introduction of the p53 gene in p53-defective tumors, followed by resveratrol treatment, may represent a novel and promising therapeutic approach in our fight against cancer," says the young author.
The article entitled "Transient transfection of wild-type p53 gene triggers resveratrol-induced apoptosis in cancer cells" is available at http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0048746
The study was funded by the National Council for Scientific and Technological Development (CNPq), the Rio de Janeiro State Foundation for Research (FAPERJ), the Ministry of Health (MS/Decit), Cancer Foundation, and the National Institute of Science and Technology for Structural Biology and Bioimaging (INBEB).
Publicase Comunicação Científica
Please use one of the following formats to cite this article in your essay, paper or report:
Científica, Publicase Comunicação. "Ingredients For A Successful Cell Death: A Sip Of Resveratrol And A Full P53." Medical News Today. MediLexicon, Intl., 16 Nov. 2012. Web.
13 Feb. 2016. <http://www.medicalnewstoday.com/releases/252788.php>
Científica, P. (2012, November 16). "Ingredients For A Successful Cell Death: A Sip Of Resveratrol And A Full P53." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.